RAF/RAS oncogenes and mismatch-repair status
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Genes of the RAF family encode kinases that are regulated by Ras and mediate cellular responses to growth signals. Activating mutations in one RAF gene, BRAF, have been found in a high proportion of melanomas and in a small fraction of other cancers. Here we show that BRAF mutations in colorectal cancers occur only in tumours that do not carry mutations in a RAS gene known as KRAS, and that BRAF mutation is linked to the proficiency of these tumours in repairing mismatched bases in DNA. Our results not only provide genetic support for the idea that mutations in BRAF and KRAS exert equivalent effects in tumorigenesis, but also emphasize the role of repair processes in establishing the mutation spectra that underpin human cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The prevalence of BRAF V600E mutations in mCRC is 8–10%, and they occur only in KRAS-WT mCRC [159,160].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [160]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Lessons from hereditary colorectal cancer
Kinzler, K. W., & Vogelstein, B. (1996) · Cell · doi:10.1016/s0092-8674(00)81333-1 · Cited by 4,919
Self-citationStabilization of β-Catenin by Genetic Defects in Melanoma Cell Lines
Rubinfeld, B., Robbins, P., El-Gamil, M., Albert, I., Porfiri, E., & Polakis, P. (1997) · Science · doi:10.1126/science.275.5307.1790 · Cited by 1,223
Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer.
Sparks, A. B., Morin, P. J., Vogelstein, B., & Kinzler, K. W. (1998) · PubMed · Cited by 1,008
Self-citationDifferential Regulation of Raf-1, A-Raf, and B-Raf by Oncogenic Ras and Tyrosine Kinases
Marais, R., Light, Y., Paterson, H. F., Mason, C. S., & Marshall, C. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4378 · Cited by 456
Mechanisms underlying losses of heterozygosity in human colorectal cancers
Thiagalingam, S., Laken, S., Willson, J. K. V., Markowitz, S. D., Kinzler, K. W., Vogelstein, B., & Lengauer, C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051625398 · Cited by 228
Self-citationPrevalence of somatic alterations in the colorectal cancer cell genome
Wang, T.-L., Rago, C., Silliman, N., Ptak, J., Markowitz, S., Willson, J. K. V., Parmigiani, G., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261714699 · Cited by 177
Self-citationOncogene activation: c-raf-1 gene mutations in experimental and naturally occurring tumors
Storm, S. M., & Rapp, U. R. (1993) · Toxicology Letters · doi:10.1016/0378-4274(93)90056-4 · Cited by 53
Research works printed but not linked: 2
- Sparks, A. B., Morin, P. J., Vogelstein, B. & Kinzler, K. W. Cancer Res. 58, 1130–1134 (1998).
- Markowitz, S. J. Clin. Oncol. 18 (suppl.), 75–80 (2000).
Cited by
Items 801–900 of 999
The distinctive molecular, pathological and clinical characteristics ofBRAF-mutant colorectal tumors
Scartozzi, M., Giampieri, R., Aprile, G., Iacono, D., Santini, D., Dell’Aquila, E., Silvestris, N., Gnoni, A., Bonotto, M., Puzzoni, M., et al. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.1047346 · Cited by 15
“Accordingly, mutations in these genes appear to be mutually exclusive [6].”
BackgroundGerm line and somatic mutations of BRAF V599E in ovarian carcinoma
Ueda, M., Eisaku, T. O. J. I., & Noda, S. (2007) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2006.00853.x · Cited by 15
High-Throughput Mutational Analysis of the Human Cancer Genome
Ma, P. C., Zhang, X., & Wang, Z. (2006) · Pharmacogenomics · doi:10.2217/14622416.7.4.597 · Cited by 16
Genetic basis and gene therapy trials for thyroid cancer.
Al‐Humadi, H., Ζάρρος, Α., Al‐Saigh, R., & Liapi, C. A. (2010) · PubMed · Cited by 19
Woo, M. M. M., Salamanca, C. M., Miller, M. W., Symowicz, J., Leung, P. C. K., Oliveíra, C., Ehlen, T. G., Gilks, C. B., Huntsman, D. D., & Auersperg, N. (2008) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2007.01171.x · Cited by 12
Frank, R., Baloch, Z. W., Gentile, C., Watt, C. D., & LiVolsi, V. A. (2013) · Endocrine Pathology · doi:10.1007/s12022-013-9289-0 · Cited by 14
Multimodal treatment strategies for locally advanced rectal cancer
Weber, G. F., Rosenberg, R., Murphy, J. E., Büschenfelde, C. M. Z., & Friess, H. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.3 · Cited by 16
Ras in digestive oncology: from molecular biology to clinical implications
Charette, N., Vandeputte, C., & Stärkel, P. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000088 · Cited by 16
“The importance of Ras for Raf activation and that of Raf in Ras downstream signalling is highlighted by the fact that Ras and Raf mutations are mutually exclusive in human tumours [21].”
BackgroundEzrin expression combined with MSI status in prognostication of stage II colorectal cancer
Slik, K., Kurki, S. H., Korpela, T., Carpén, O., Korkeila, E. A., & Sundström, J. T. T. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185436 · Cited by 14
Genomic and epigenomic biomarkers in colorectal cancer: From diagnosis to therapy
Bañobre, J. R., & Goel, A. (2021) · Advances in cancer research · doi:10.1016/bs.acr.2021.02.008 · Cited by 20
Asl, J. M., Almasi, S., & Tabatabaie, M. A. (2013) · Pakistan Journal of Biological Sciences · doi:10.3923/pjbs.2014.565.569 · Cited by 14
Mechanisms of Oncogene Activation
Botezatu, A., Iancu, I. V., Popa, O., Plesa, A., Manda, D. A., Huică, I., Vlădoiu, S., Anton, G., & Badiu, C. (2016) · InTech eBooks · doi:10.5772/61249 · Cited by 23
Dobre, M., Comanescu, M. V., Arsene, D. E., Iosif, C., & Bussolati, G. (2013) · PubMed · Cited by 21
Bougatef, K., Coulet, F., Rouissi, K., Kourda, N., Omrane, I., Raja, M., Sarra, B., Soubrier, F., & Amel, B. A. E. (2011) · Cancer Biomarkers · doi:10.3233/cbm-2011-0222 · Cited by 13
“These mutations alter the protein causing impaired GTPase activity resulting in constitutively active protein, leading to a continual stimulus of cell proliferation by a variety of signalling pathways [26, 31].”
Zhao, Y., Miyashita, K., Ando, T., Kakeji, Y., Yamanaka, T., Taguchi, K., Ushijima, T., Oda, S., & Maehara, Y. (2008) · Gene · doi:10.1016/j.gene.2008.07.014 · Cited by 14
A subset of colorectal carcinomas express c-KIT protein independently of BRAF and/or KRAS activation
Preto, A., Moutinho, C., Velho, S., Oliveíra, C., Rebocho, A. P., Figueiredo, J., Soares, P., Lopes, J. M., & Seruca, R. (2007) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-007-0420-9 · Cited by 14
“In sporadic CRC, oncogenic BRAF mutations are found in about 12% of the tumours analysed, mainly in MSI cases (31–45%) [9, 10, 22, 25].”
Muhammad, S., Jiang, Z., Liu, Z., Kaur, K., & Wang, X. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2078-6891.2012.044 · Cited by 19
Zhang, D., Tang, W., Niu, H., Tse, W., Ruan, H., Dolznig, H., Knösel, T., Karl-Heinz, F., Themanns, M., Wang, J., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.11.024 · Cited by 14
Prognostic value of specific KRAS mutations in patients with colorectal peritoneal metastases
Tonello, M., Baratti, D., Sammartino, P., Giorgio, A. D., Robella, M., Sassaroli, C., Framarini, M., Valle, M., Macrì, A., Graziosi, L., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102976 · Cited by 13
“6 KRAS mutations have been found in w 40% of CRC patients (all stages), with the majority (90”
BackgroundAfonso, F. J. A., Anido, U., Calvo, O. F., Vázquez‐Estévez, S., León‐Mateos, L., Lázaro, M., Ramos, M., & Antón-Aparicio, L. M. (2013) · Clinical & Translational Oncology · doi:10.1007/s12094-012-0985-x · Cited by 13
“Significantly, B-Raf and Ras mutations are restricted to the same tumor types, usually in a mutually exclusive fashion, suggesting a possible signaling pathway in which Ras activates B-Raf in these tumors [14–17].”
Steele, C. W., Whittle, T., & Smith, J. J. (2019) · Chinese Clinical Oncology · doi:10.21037/cco.2019.08.16 · Cited by 14
Current Approaches for Predicting a Lack of Response to Anti-EGFR Therapy inKRASWild-Type Patients
Er, T., Chen, C.-C., Bujanda, L., & Herreros‐Villanueva, M. (2014) · BioMed Research International · doi:10.1155/2014/591867 · Cited by 16
Combination therapy targeting Raf-1 and MEK causes apoptosis of HCT116 colon cancer cells
Subramanian, R. R., & Yamakawa, A. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1602 · Cited by 13
Rapid Screening of 4000 Individuals for Germ-line Variations in the BRAF Gene
James, M. R., Dumeni, T., Stark, M. S., Duffy, D. L., Montgomery, G. W., Martin, N. G., & Hayward, N. K. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2006.070169 · Cited by 13
K-ras oncogene mutation in pterygium
Öztürk, B., Yıldırım, M. S., Zamanı, A. G., & Bozkurt, B. (2016) · Eye · doi:10.1038/eye.2016.254 · Cited by 13
Yamada, R., Yamaguchi, T., Iijima, T., Wakaume, R., Takao, M., Koizumi, K., Hishima, T., & Horiguchi, S. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-018-1238-y · Cited by 12
“Biomarker analyses have detected the BRAF V600E mutation in most sporadic MSI cancers [7].”
BackgroundRodríguez‐Casanova, A., Bao‐Caamano, A., Lago‐Lestón, R. M., Brozos-Vázquez, E., Costa‐Fraga, N., Ferreirós-Vidal, I., Abdulkader, I., Vidal-Ínsua, Y., Rivera, F. V., Folgar, S. C., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194487 · Cited by 13
Dissecting cancer heterogeneity
Dornan, D., & Settleman, J. (2011) · Nature Biotechnology · doi:10.1038/nbt.2063 · Cited by 13
Veganzones, S., Maestro, M. L., Rafael, S., de la Orden, V., Vidaurreta, M., Mediero-Valeros, B., Espantaleon, M., Cerdán, J., & Díaz‐Rubio, E. (2015) · Tumor Biology · doi:10.1007/s13277-014-3027-1 · Cited by 15
“BRAF mutation is also associated with MSI pathway and with hMLH1 methylation [34, 35].”
BackgroundResultMetastasis of Colorectal Cancer
Beauchemin, N., & Huot, J. (2010) · Cancer metastasis · doi:10.1007/978-90-481-8833-8 · Cited by 16
BRAF mutations in sporadic colorectal carcinoma from polish patients.
Wójcik, P., Okoń, K., Osuch, C., Klimkowska, A., & Tomaszewska, R. (2010) · PubMed · Cited by 13
Green, D. E., Jayakrishnan, T., Hwang, M., Pappas, S. G., Gamblin, T. C., & Turaga, K. K. (2015) · Frontiers in Surgery · doi:10.3389/fsurg.2014.00050 · Cited by 12
“We did not encounter patients that exhibited both BRAF and KRAS mutations simultaneously,which is also consistent with previous reports (15).”
BackgroundResultLoss of the Ras Regulator RASAL1: Another Route to Ras Activation in Colorectal Cancer
Bernards, A., & Settleman, J. E. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.11.024 · Cited by 12
Tumor biology and cancer therapy – an evolving relationship
Seufferlein, T. T. W., Ahn, J., Krndija, D., Lother, U., Adler, G., & von Wichert, G. (2009) · Cell Communication and Signaling · doi:10.1186/1478-811x-7-19 · Cited by 12
“In addition, in a recent study mutations were detected in 10% of the patients in the RAS-activated kinase BRAF [ 36 ].”
Padhan, N., Nordling, T. E. M., Sundström, M., Åkerud, P., Birgisson, H., Nygren, P., Nelander, S., & Claesson, L. (2016) · BMC Cancer · doi:10.1186/s12885-016-2725-z · Cited by 13
“Tumors may have mutations either in KRAS or BRAF though, as a rule, not in both [11].”
BackgroundIbrahiem, A. T., Fawzy, M. S., Alsel, B. T. A., & Toraih, E. A. (2020) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23679 · Cited by 12
Hinoi, T. (2021) · Journal of the Anus Rectum and Colon · doi:10.23922/jarc.2021-009 · Cited by 15
“Although sporadic MSI-high colorectal tumors have an increased frequency of BRAF V600E variants[47], BRAF variants are rarely detected in MSI-high tumors in patients with LS[48].”
BackgroundXiao, H., Zhang, Q., Shen, J., Bindokas, V. P., & Xing, H. R. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0124 · Cited by 12
RetractedEruptive Squamous Cell Carcinomas after Vemurafenib Therapy
Mays, R. M., Curry, J. L., Kim, K., Tsai, K. Y., Arora, A., Khan, F. A., Ramirez‐Fort, M. K., & Ciurea, A. M. (2013) · Journal of Cutaneous Medicine and Surgery · doi:10.2310/7750.2013.12092 · Cited by 12
López-Correa, P., Lino-Silva, L. S., Gamboa‐Domínguez, A., Zepeda‐Najar, C., & Salcedo‐Hernández, R. A. (2018) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-018-0132-1 · Cited by 12
Kondelin, J., Salokas, K., Saarinen, L., Ovaska, K., Rauanheimo, H., Plaketti, R., Hamberg, J., Liu, X., Yadav, L., Gylfe, A. E., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708552 · Cited by 13
Hatthakarnkul, P., Quinn, J. A., Matly, A., Ammar, A., Wyk, H. C. V., McMillan, D., & Edwards, J. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103490 · Cited by 12
BRAF in Papillary Thyroid Carcinoma
Lanzilotta, S. G., Grammatica, L., Paradiso, A., & Simone, G. (2007) · Analytical Cellular Pathology · doi:10.1155/2007/489604 · Cited by 12
“which are included in the kinase domain [14,51].”
BackgroundRecognition and binding of mismatch repair proteins at an oncogenic hot spot
Edelbrock, M. A., He, H., Schroering, A. G., Fernström, M. J., Bathala, S., & Williams, K. J. (2005) · BMC Molecular Biology · doi:10.1186/1471-2199-6-6 · Cited by 12
“Although the contribution of MMR to highly mutable genomic sites other than microsatellite sequences is largely unknown, several specific genetic mutations involved in neoplastic progression, including ras-activating mutations, have been reported as frequent occurrences in HNPCC and other MSI tumors [7, 8 ].”
Pu, X., Pan, Z., Huang, Y., TIAN, Y., Guo, H., Wu, L., HE, X., Chen, X., Zhang, S., & Lin, T. (2012) · Oncology Letters · doi:10.3892/ol.2012.963 · Cited by 12
“It has been reported that BRAF and KRAS mutations are mutually exclusive (24,25).”
BackgroundKonishi, K., Takimoto, M., Kaneko, K., Makino, R., Hirayama, Y., Nozawa, H., Kurahashi, T., Kumekawa, Y., Yamamoto, T., Ito, H., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602911 · Cited by 12
“Previous studies (Rajagopalan et al, 2002; Wang et al, 2003; Domingo et al, 2004; Koinuma et al, 2004) have reported that BRAF mutations occur more frequently in”
BackgroundInfluentialGeorgieva, M., Krasteva, M. E., Angelova, E., Ralchev, K., Dimitrov, V., Bozhimirov, S., Georgieva, E., & Berger, M. (2008) · Oncology Reports · doi:10.3892/or.20.1.3 · Cited by 12
“The somatic mutations of B-raf are associated with 60% of malignant melanomas and occur with moderate to high frequency in colorectal (8), ovarian (9) and papillary thyroid carcinomas (10), indicating mutations of B-raf as critical promoters of malignancy.”
Kim, Y. H., Yim, H., Lee, Y.-H., Han, J. H., Lee, K. B., Lee, J., Soh, E. Y., Jeong, S., & Kim, J. (2015) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2015.10.10 · Cited by 12
“Mutations in BRAF constitutively activate the MAPK pathway, allowing human cancers to develop and progress.(1,2) Of the various BRAF mutations, BRAFV600E, a valine to glutamic acid substitution at codon 600, is the most common.”
Epigenomic annotation of noncoding mutations identifies mutated pathways in primary liver cancer
Lowdon, R. F., & Wang, T. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174032 · Cited by 14
“For example, in colorectal cancer, BRAF mutations are mutually exclusive with mutations in KRAS [65], indicating that a single alteration of the activity of a pathway member is sufficient to induce misregulation of that pathway.”
The Ras Signalling Pathway as a Target in Cancer Therapy
Graham, K., & Olson, M. F. (2007) · Springer eBooks · doi:10.1007/978-3-540-31209-3_8 · Cited by 12
Precision Medicine in Colorectal Cancer: Evolving Genomic Landscape and Emerging Consensus
Fisher, K. W., Antonio Lopez-beltran, B., Montironi, R., & Liang Cheng, C. (2015) · Future Oncology · doi:10.2217/fon.15.219 · Cited by 11
Deciphering the Key Features of Malignant Tumor Microenvironment for Anti-cancer Therapy
Shang, B., Zhang, G., Pan, Y., & Zhou, Q. (2012) · Cancer Microenvironment · doi:10.1007/s12307-012-0108-9 · Cited by 11
Management of Microsatellite Instability High (MSI-H) Gastroesophageal Adenocarcinoma
Zhou, K. I., Hanks, B. A., & Strickler, J. H. (2023) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-023-01003-5 · Cited by 11
“In contrast, BRAF V600E mutations, which commonly occur in sporadic MSI-H colorectal cancer, are notably absent in MSI-H gastric cancers [2, 24, 25].”
Comprehensive review of signaling pathways and therapeutic targets in gastrointestinal cancers
Ji, P., Chen, T., Li, C. R., Zhang, J., Li, X., & Zhu, H. P. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104586 · Cited by 11
Wild-type KRAS and BRAF could predict response to Cetuximab in Chinese colorectal cancer patients
Gao, J., Wang, T., Yu, J., Li, Y., & Shen, L. (2011) · Chinese Journal of Cancer Research · doi:10.1007/s11670-011-0271-4 · Cited by 11
“3% (14/168), which was similar to others[19,20].”
Giorgio, A. D., Santullo, F., Halabieh, M. A. E., Lodoli, C., Abatini, C., Calegari, M. A., Martini, M., Rotolo, S., & Pacelli, F. (2021) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-021-05073-3 · Cited by 11
Imajo, M., Kondoh, K., Yamamoto, T., Nakayama, K., Nakajima‐Koyama, M., & Nishida, E. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00012-17 · Cited by 12
Identifying pathways affected by cancer mutations
Iengar, P. (2017) · Genomics · doi:10.1016/j.ygeno.2017.12.004 · Cited by 11
BRAF, K-ras and BAT26 mutations in colorectal polyps and stool.
Jin, Y.-M., Li, B.-J., Qu, B., & Du, Y.-J. (2006) · Europe PMC (PubMed Central) · doi:10.3748/wjg.v12.i32.5148 · Cited by 11
Loupakis, F., Vasile, E., Santini, D., Masi, G., Falcone, A., & Graziano, F. (2007) · Pharmacogenomics · doi:10.2217/14622416.9.1.55 · Cited by 14
Kadiyska, T., Konstantinova, D. V., Atanasov, V. R., Kremensky, I. M., & Mitev, V. (2007) · Cancer Detection and Prevention · doi:10.1016/j.cdp.2007.04.001 · Cited by 11
Rennert, G., Kislitsin, D., Brenner, D. E., Rennert, H. S., & Lev, Z. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.01.023 · Cited by 11
“Other such markers [21,22] may identify K-ras negative malignancies, thus further increasing the efficacy of the screening process.”
BackgroundColorectal carcinogenesis via serrated route
Stefanius, K. (2011) · Cited by 11
Fernandes, M. S., Melo, S., Velho, S., Carneiro, P., Carneiro, F., & Seruca, R. (2016) · Oncotarget · doi:10.18632/oncotarget.11843 · Cited by 11
“Of significance is the fact that KRAS and BRAF mutations are preferentially found as alternative molecular alterations and thus are not frequently observed in the same tumor suggesting that KRAS and BRAF have distinct roles in the development and progression of CRC [5, 9].”
BackgroundGenomic Landscapes of Cancers: Prospects for Targeted Therapies
Bleeker, F. E., & Bardelli, A. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.12.1629 · Cited by 10
Self-citationLow dose radiation regulates BRAF-induced thyroid cellular dysfunction and transformation
Kaushik, N., Kim, M.-J., Kaushik, N. K., Myung, J. K., Choi, M.-Y., Kang, J.-H., Cha, H., Kim, C.-S., Nam, S.-Y., & Lee, S. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0322-x · Cited by 12
“Recently activating somatic mutations in the BRAF proto-oncogene has been discovered in various malignancies, such as in melanoma (60–70% of cases) [1, 2], colon cancer (10%) [3, 4] including thyroid cancer (35–70%) [5, 6].”
Background[Clinical significance of BRAF mutations in colorectal cancer].
Lièvre, A., Rouleau, É., Buecher, B., & Mitry, E. (2010) · PubMed · doi:10.1684/bdc.2010.1225 · Cited by 18
Culturing intestinal stem cells: applications for colorectal cancer research
Fujii, M., & Sato, T. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00169 · Cited by 10
Kim, S. J., Kim, H. R., Kim, S. H., Han, J. H., Cho, Y. B., Yun, S. H., Lee, W. Y., & Kim, H. C. (2014) · Annals of Surgical Treatment and Research · doi:10.4174/astr.2014.87.3.123 · Cited by 11
Analysis of factors influencing molecular testing at diagnostic of colorectal cancer
Thiebault, Q., Défossez, G., Karayan, L., Ingrand, P., Silvain, C., & Tougeron, D. (2017) · BMC Cancer · doi:10.1186/s12885-017-3759-6 · Cited by 12
“Since KRAS and BRAF mutations are mutually exclusive [8], BRAF testing is performed only in KRAS WT tumours.”
BackgroundShifting the Focus of Signaling Abnormalities in Colon Cancer
Brown, M. A., & Ried, T. (2022) · Cancers · doi:10.3390/cancers14030784 · Cited by 13
BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAFV600E colorectal cancer
Jenkins, L. J., Luk, I. Y., Chionh, F. J. M., Tan, T., Needham, K. A., Ayton, J., Reehorst, C. M., Vukelic, N., Sieber, O. M., Mouradov, D., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06478-z · Cited by 11
Taniguchi, H., Uehara, K., Ishikawa, T., Okochi, O., Akazawa, N., Okuda, H., Hasegawa, H., Shiozawa, M., Kataoka, M., Satake, H., et al. (2025) · Cancers · doi:10.3390/cancers17030399 · Cited by 10
Lindsay, C. R., Spiliopoulou, P., & Waterston, A. M. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834014566619 · Cited by 9
“Melanoma activating mutations of BRAF and NRAS are generally mutually exclusive, a finding which suggests they stimulate the same linear pathway involving MAPK deregulation [Davies et al. 2002; Goel et al. 2006; Rajagopalan et al. 2002].”
BackgroundFelderbauer, P., Stricker, I., Schnekenburger, J., Bulut, K., Chromik, A. M., Belyaev, O., Müller, C., Uhl, W. H., Tannapfel, A., & Schmidt, W. E. (2008) · Digestion · doi:10.1159/000165108 · Cited by 10
“V600E leads to a conversion of valine 600 to glutamic acid, resulting in the insertion of a negatively charged residue adjacent to the phosphorylation site at T598. This may mimic regulatory phosphorylation leading to a constitutive activation of BRAF independent of RAS [”
BackgroundMolecular Diagnostic Applications in Colorectal Cancer
Huth, L., Jäkel, J., & Dahl, E. (2014) · Microarrays · doi:10.3390/microarrays3030168 · Cited by 14
“Mutations of the BRAF gene, which were found at an early stage of CRC carcinogenesis, occur in 5%–15% of overall CRC [9].”
BackgroundSchneider, M., Scholtka, B., Gottschalk, U., Faiss, S., Schatz, D., Berghof-Jäger, K., & Steinberg, P. (2010) · Cancers · doi:10.3390/cancers3010091 · Cited by 9
“However, earlier studies, based on the analysis of DNA isolated from formalin-fixed and paraffin-embedded samples, postulated that B-Raf and K-Ras mutations were mutually exclusive in precancerous colorectal lesions [15,16,34].”
ResultNguyen, H. T., Le, T., Duong, Q., Tatipamula, V. B., & Nguyen, B. V. (2020) · Oncology Letters · doi:10.3892/ol.2020.12302 · Cited by 14
Martin, M., Mundade, R., Hartley, A.-V., Jiang, G., Jin, J., Sun, S., Safa, A. R., Sandusky, G. E., Liu, Y., & Lu, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052732 · Cited by 10
The role of Wnt, ARL4C, and Sema3A in developmental process and disease pathogenesis
Fujii, S., & Kiyoshima, T. (2023) · Pathology International · doi:10.1111/pin.13325 · Cited by 11
“BRAF reportedly forms a complex with wild‐type RAF1 (also known as C‐RAF) and then promotes RAF1 kinase activity, thereby stimulating the MEK/ERK pathway.(131,132) Raf1 Kinase Inhibitor I suppressed the activation of ERK1/2 and the expression of ARL4C, and RAF1 knockdown decreased the ARL4C expression in AM‐1 cells.”
BackgroundPerchiniak, E. M., & Groden, J. L. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139046947.048 · Cited by 9
Wanebo, H. J., & Berz, D. (2010) · Journal of Surgical Oncology · doi:10.1002/jso.21691 · Cited by 11
“To date, the question remains contentious if the Braf mutation status, which are mutually exclusive with Kras mutations [46,47], is a prognostic marker or a response predictor to EGFR-directed moAb therapy [26], although an emerging body of literature describes Braf mutations as negative response predictors for cetuxi…”
BackgroundDevelopment and Applications of a BRAF Oligonucleotide Microarray
Kim, I.-J., Kang, H. C., Jang, S. G., Ahn, S.-A., Yoon, H., & Park, J.-G. (2007) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2007.060072 · Cited by 9
Overview of Colorectal Cancer Genetics
Gryfe, R. (2009) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2009.08.004 · Cited by 9
“BRAF acts downstream of K-ras and the vast majority of BRAF mutations observed in colorectal cancer consist of a single nucleotide substitution, V600E (previously named V599E).(27)”
BackgroundAmaki-Takao, M., Yamaguchi, T., Natsume, S., Iijima, T., Wakaume, R., Takahashi, K., Matsumoto, H., & Miyaki, M. (2016) · Oncology · doi:10.1159/000447402 · Cited by 9
Inhibition of Telomerase by Targeting MAP Kinase Signaling
Xu, D., Li, H., & Liu, J. (2007) · Methods in molecular biology · doi:10.1007/978-1-60327-070-0_12 · Cited by 9
A case report of ascending colon adenosquamous carcinoma with BRAF V600E mutation
Ishida, H., Yamaguchi, T., Chiba, K., Iijima, T., & Horiguchi, S. (2017) · International Cancer Conference Journal · doi:10.1007/s13691-017-0283-0 · Cited by 10
Cancers colorectaux avec mutation V600E de BRAF : où en sommes-nous ?
Lièvre, A., de la Fouchardière, C., Samalin, E., Benoist, S., Phelip, J., André, T., & Lledo, G. (2020) · Bulletin du Cancer · doi:10.1016/j.bulcan.2020.04.017 · Cited by 12
Maietta, I., Viscusi, E., Laudati, S., Iannaci, G., D’Antonio, A., Melillo, R. M., Motti, M. L., & Falco, V. D. (2024) · Cells · doi:10.3390/cells13181546 · Cited by 8
Comprehensive genomic dependency landscape of a human colon cancer organoid
Khalili, S., Mohseninia, A., Liu, C., Banister, C. E., Heine, P., Khazan, M., Morrison, S. E., Gokare, P. R., Cowley, G. S., Weir, B. A., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-07822-5 · Cited by 11
“This tumor has notable somatic mutations in the DNA-repair pathway 24 – 26 genes MLH3, MSH3 and in RNF43 27 , BRAF 28 , and PTEN genes 29 (Table1andSupplementaryData5).”
Stamatelli, A., Saetta, A. A., Bei, T., Kavantzas, N., Michalopoulos, N. V., Patsouris, E., & Aroni, K. (2011) · Pathology & Oncology Research · doi:10.1007/s12253-011-9363-1 · Cited by 8
“They have also been associated with mismatch repair (MMR) deficient colorectal cancers [9, 10].”
BackgroundKim, J. E., Kim, K. K., Kim, S. Y., Lee, J., Park, S. H., Park, J. O., Park, Y. S., Lim, H. Y., Kang, W. K., & Kim, S. T. (2017) · Journal of Cancer · doi:10.7150/jca.19582 · Cited by 9
“RAS/RAF/MAPK signaling is considered the key modulator of sensitivity and resistance to anti-EGFR therapy in CRC [9-13].”
BackgroundKundu, S., Ali, M. A., Handin, N., Padhan, N., Larsson, J., Karoutsou, M., Ban, K. H.-K., Wiśniewski, J. R., Artursson, P., He, L., et al. (2018) · Genome Medicine · doi:10.1186/s13073-017-0511-4 · Cited by 11
“Mutations in KRAS and BRAF are mutually exclusive in CRC, suggesting both confer the same phenotype [3].”
BackgroundOncogenic Genetic Alterations in Non-Small-Cell Lung Cancer (NSCLC) in Southwestern China
Ma, Y., Li, Q., Du, Y., Chen, W., Zhao, G., Liu, X., Li, H., Liu, J., Shen, Z., Ma, L., et al. (2020) · Cancer Management and Research · doi:10.2147/cmar.s266069 · Cited by 11
Wagner, S., Beger, N., Matschos, S., Szymanski, A., Przybylla, R., Bürtin, F., Prall, F., Linnebacher, M., & Mullins, C. S. (2021) · Cancers · doi:10.3390/cancers13184717 · Cited by 10
Untangling the KRAS mutated lung cancer subsets and its therapeutic implications
Kulshrestha, R., Kumar, P., Singh, A., Nupur, K., Spalgias, S., Mrigpuri, P., & Rajkumar (2021) · Molecular Biomedicine · doi:10.1186/s43556-021-00061-0 · Cited by 8
Loupakis, F., Cremolini, C., Fontanini, G., Stasi, I., Salvatore, L., & Falcone, A. (2009) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834009348984 · Cited by 9
“About 10% of CRCs bear this mutation, which is mutually exclusive with KRAS ones [Rajagopalan et al. 2002].”
BackgroundVerbruggen, M. B., Sieben, N. L. G., Roemen, G. M. J. M., Rockx, D., van Diest, P. J., Verheijen, R. H. M., & Dorsman, J. C. (2009) · International Journal of Gynecological Cancer · doi:10.1111/igc.0b013e3181a83119 · Cited by 8
Σαμαρά, Μ., Kapatou, K., Ιωάννου, Μ., Kostopoulou, E., Papamichali, R., Papandreou, C. N., Athanasiadis, A., & Koukoulis, G. Κ. (2015) · Genetics and Molecular Research · doi:10.4238/2015.december.14.6 · Cited by 10
Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives
Battaglin, F., Puccini, A., Naseem, M., Schirripa, M., Berger, M. D., Tokunaga, R., McSkane, M., Khoukaz, T., Soni, S., Zhang, W., et al. (2018) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2018.04 · Cited by 9
Metadata
- Authors
- Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E.
- Affiliations
- Johns Hopkins University (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Velculescu, Victor E.
- Venue
- Nature
- Published
- 2002-08-29
- Volume
- 418
- Issue
- 6901
- Pages
- 934-934
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1985035689
- Cited by
- 1,224
- References
- 8
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 29 · 2023: 30 · 2022: 26 · 2021: 42 · 2020: 38 · 2019: 35 · 2018: 41 · 2017: 42 · 2016: 51 · 2015: 76 · 2014: 65 · 2013: 74 · 2012: 78
- FWCI
- 37.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- BRAF mutation, KRAS mutation, oncogenic Ras, DNA mismatch repair, colorectal cancer, melanoma, carcinogenesis, DNA repair, mutation spectrum, growth factor signaling
- MeSH terms
- DNA Damage, DNA Repair, Gene Frequency, Humans, Mutation, Oncogenes, Genes, ras, Colorectal Neoplasms, Proto-Oncogene Proteins c-raf, Base Pair Mismatch
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.